Starling Oncology (STLNW) Share-based Compensation (2021 - 2026)

Starling Oncology (STLNW) has reported Share-based Compensation for 6 consecutive years, with $1.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Share-based Compensation rose 42.29% year-over-year to $1.1 million; the trailing twelve-month figure through Jun 2026 stood at $5.1 million (down 13.43% YoY), and the FY2025 full-year result was $4.6 million, down 59.19% from the prior year.
• Share-based Compensation declined to $1.1 million in Q2 2026 per STLNW's latest filing, from $1.7 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $8.6 million in Q1 2022 and bottomed at $752000.0 in Q2 2025.
• Historically, Share-based Compensation has averaged $3.6 million across 5 years, with a median of $3.7 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Share-based Compensation surged 20264.29% in 2022, then plunged 77.8% in 2025.
• Over 5 years, Share-based Compensation stood at $6.1 million in 2022, then sank by 32.8% to $4.1 million in 2023, then tumbled by 68.4% to $1.3 million in 2024, then gained by 2.17% to $1.3 million in 2025, then fell by 18.75% to $1.1 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $1.1 million, $1.7 million, and $1.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.